Safety, Tolerability, and Pharmacokinetics of Senaparib, a Novel PARP1/2 Inhibitor, in Chinese Patients With Advanced Solid Tumors: A Phase I Trial.
Junning CaoHongqian GuoDongmei JiWeina ShenShun ZhangChih-Yi HsiehSui Xiong CaiYe Edward TianCong XuPin ZhangBinghe XuPublished in: The oncologist (2023)
NCT03508011.